Growing FDA Approvals are Anticipated to Drive the Growth of the Pediatric Drugs Market

The global pediatric drug market is projected to exhibit considerable growth during the forecast period (2019-2025). The high prevalence of the pediatric disorder, the rapid increase in the R&D activities related to the drug development process for the treatment of this disorder by the key players operating is a major factor anticipated to fuel the pediatric drug market during the forecast period. Novartis International AG, Genetech, Inc., Medimmune LLC, Johnson & Johnson Services Inc., F. Hoffman La Roche, Merck & Co. Inc., Pfizer Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline Plc, Bristol-Myers Squibb, Eli Lilly and Co., and so on are the key market players operating in the global pediatric drugs market.

Browse the full report description Global Pediatric Drugs Market Size, Share & Trends Analysis Report, by Drug Type (Allergy and Respiratory Drugs, Cancer Therapies, Cardiovascular Drugs, Gastrointestinal Drugs, and Others), by Route of Administration (Oral, Topical, Parenteral, and Other), by Application (Pediatric Clinical Pharmacology, Pediatric Pharmacotherapy, and Pediatric Pharmacy) Forecast Period (2020-2026) at https://www.omrglobal.com/industry-reports/pediatric-drugs-market

In March 2020, Genetech, Inc. had received US FDA acceptance of new drug application and two new supplemental drug applications for the influenza antiviral Xofluza for children. The new drug application is for a new formulation of Xofluza (baloxavir marboxil), a 1 dose granule (2 mg/mL) through the oral route of administration. The company is also in the waiting list of getting approval for baloxavir marboxil for the treatment of acute uncomplicated influenza in healthy children aged between 1 and 12 years, who have been symptomatic for no more than 48 hours, and as postexposure prophylaxis for influenza in people aged older than 1 year for both oral suspension and tablet form.

In February 2019, MedImmune LLC had received US FDA approval for its Breakthrough Therapy Designation (BTD) for MEDI8897. MEDI8897 is an extended half-life respiratory syncytial virus (RSV) of a monoclonal antibody (mAb). This therapy is being developed to prevent lower respiratory tract infection (LRTI) that was caused by RSV. A BTD is capable to accelerate the development of medicines that are used to treat a serious condition. The launch of MEDI8897 is a result of a partnership between the company and Sanofi Pasteur.

In May 2018, Novartis International AG had received US FDA approval for Gilenya (fingolimod) for the treatment of children and adolescents between the ages of 10 to 18 years having relapsing forms of multiple sclerosis (RMS). Gilenya is considered to be the first disease-modifying therapy used for the treatment of patients having RMS. With this approval the age range for Gilenya, which was previously approved for patients aged 18 years and older with RMS got an extension.

Global Pediatric Drugs Market Segmentation

By Product Type

• Allergy and Respiratory Drugs
• Cancer Therapies
• Cardiovascular Drugs
• Gastrointestinal Drugs
• Others

By Route of administration

• Oral 
• Topical
• Parenteral
• Other

By Application

• Pediatric Clinical Pharmacology
• Pediatric Pharmacotherapy
• Pediatric Pharmacy

Global Pediatric Drugs Market Segmentation by region